Correlation between Residual Renal Function and Hypertension in Regular Haemodialysis Patients

Objective: To evaluate the correlation between residual renal function and hypertension in regular haemodialysis patients. Background: Initiating chronic dialysis treatment gives end-stage renal disease patients a new lease on life. However, the annual mortality rate in dialysis patients is ~20% and quality of life is substantially reduced. Patients and Methods: This study was carried out on a reasonable number of subjects on regular haemodialysis divided into two groups. All were given informed consent and, the study was approved by the ethics committee of Menoufia University. Results: There was significant relation between presence of residual renal function and hypertension in patients with ESRD on regular haemodialysis, but the relation between residual renal function and control of hypertension is not statistically significant. 40% of group 1 were hypertensive, 66.7% of group 2 patients were hypertensive, the interdialytic weight gain mean was 1.42 in group 1 and 2.37 in group 2. Control of hypertension was achieved in 63.6% of group 1 patients by one drug, 27.3% patients by 2 drugs; however 9.1% of patients need 3 drugs to control their blood pressure, while in group 2 40% of patients were controlled by one drug, 45% with 2 drugs and 15% need 3 drugs to control blood pressure. Conclusion: There is significant relation between presence of residual renal function and hypertension in patients with ESRD on regular haemodialysis, but the relation between residual renal function and control of hypertension is not statistically significant.


Introduction
Initiating chronic dialysis treatment gives end-stage renal disease patients a new lease on life. However, the annual mortality rate in dialysis patients is ~20% and quality of life is substantially reduced [1].
Observational studies have shown that preservation of residual renal function [RRF] in dialysis patients is a prognostic and independent factor in patient survival and quality of life [2], also when RRF is almost completely lost. A higher dialysis dose cannot compensate for declining RRF. The increased benefit of RRF compared to dialysis clearance is likely attributable to a better water and salt balance, the renal ability to clear and metabolize various substances including middle-sized molecules such as b-2-microglobulin and protein-bound substances as well as the endocrine functions of the kidneys.
There is an increased focus on preserving RRF in dialysis patients [3].
In addition to providing small solute clearance, RKF continues to maintain important metabolic, hemodynamic, and endocrine functions, and plays a crucial role in maintaining the overall cardiovascular health, nutritional status, mineral metabolism balance and well-being of patients undergoing dialysis [4].
RRF remains important even after the beginning of dialysis. RRF contributes significantly to the overall health and well-being of patients on dialysis [5]. It plays an important role in maintaining fluid balance, phosphorus control, nutrition, and removal of middle molecular uremic toxins and shows inverse relationships with valvular calcification and cardiac hypertrophy in patients on dialysis. Decline in RRF also contributes significantly to anemia, inflammation, and malnutrition in patients on dialysis [6].
Whereas the role of RRF for survival is well recognized in the peritoneal dialysis population, it has not received much attention in the hemodialysis population. In a recent study by [7], there were strong data showing that RRF contributes significantly to improved outcomes in hemodialysis patients and that efforts to preserve it are warranted. However, comparative outcome studies should be controlled for the presence of RRF.
The rate of RRF decline has been observed to be faster among HD patients compared to that of PD patients [8].
Comparison of dialysis modality revealed that intradialytic hypotension and volume depletion were most associated with the earlier onset anuria that was frequently observed in the hemodialysis population [9]. Hypertension is a strong [particularly the systolic component] and indepen-Open Journal of Nephrology dent risk factor for cardiovascular disease in the general population [11]. It occurs in an estimated 72 million people in the United States. Hypertension is the second leading cause of end-stage renal disease [ESRD] in the United States and accounts for 30% of the ESRD population. Over the past 2 decades, the prevalence and incidence of ESRD have been increasing [12].
Hypertension is both a cause and consequence of kidney disease, as the prevalence of hypertension in patients on dialysis is as high as 90%. It is associated with an annual mortality of 23%, mainly from cardiovascular disease. Interestingly, only a minority of patients on hemodialysis have satisfactory blood pressure control; there is better control in the peritoneal dialysis population. Reducing the morbidity and mortality associated with hypertension A range of strategies may be used and should be understood to improve control of blood pressure. To reduce the disease burden in patients with ESRD, vigorous control of hypertension is recommended [13].
In this study we are going to evaluate the impact of preserved residual renal function on prevalence and management of hypertension in patients on regular haemodialysis.

Patients and Methods
This study was conducted on sixty end stage renal disease patients who are un- techniques. Urine volumes less than 100 mL/d were discarded, and those patients were assumed to have no residual renal function. All patients had their blood pressure measured before and after 10 consecutive hemodialysis treatments. The SBP and DBP were immediately obtained before the HD session using the arm opposite the AV fistula and represented the average of the last ten HD sessions. Open Journal of Nephrology

Statistical Analysis
Data were fed to the computer and analyzed using IBM SPSS software package version 20.0. [Armonk, NY: IBM Corp] Qualitative data were described using number and percent. The Kolmogorov-Smirnov test was used to verify the normality of distribution Quantitative data were described using range [minimum and maximum], mean, standard deviation and median. Significance of the obtained results was judged at the 5% level.
The used tests were Chi-square test for categorical variables, to compare between different groups. Mann Whitney test, or abnormally distributed quantitative variables, to compare between two studied groups. SPSS is short for statistical package for social science, and it is used by various kinds of researchers for complex statistical data analysis.

Results
The descriptive demographic data showed that regarding mean age of studied There was no significant difference between both groups regarding age and gender.
Increasing the mean age of ESRD patients reflects the improvement of health care for such type of patients, however we still away from developed countries as mean age in United State is 61.1 years [14] and in United Kingdom [UK] is 65.9 years [15].
Distribution of the studied groups as regard Etiology of ESRD shows that the commonest cause is Diabetes mellitus (DM) with 46.7% in group 1 and 36.7% in group 2. There was no statistically significant difference between groups regarding the cause of RF. Also 40% of group 1 were hypertensive, 66.7% of group 2 patients were hypertensive. This table shows statistically significant difference between groups regarding hypertension [ Table 2].
There was highly statistically significant difference between both groups regarding interdialytic weight gain [ Table 3].
There was no statistically significant relation between interdialytic weight gain and hypertension in group 1 patients [ Table 4].
There is statistically significant relation between residual renal function and intradialytic hypertension in group 1 patients [ Table 5].
Control of hypertension was achieved in 63.6% of group 1 patients by one drug, 27.3% patients by 2 drugs; however 9.1% of patients need 3 drugs to control their blood pressure, while in group 2, 40% of patients were controlled by one drug, 45% with 2 drugs and 15% need 3 drugs to control blood pressure and there is no statistically significant difference between groups [ Table 6]. Open Journal of Nephrology

Discussion
Our study was conducted entirely on regular HD patients, because this is the commonly available type of renal replacement therapy in Egypt; however Biesen van et al. [16] showed that RRF is preserved longer on PD type of therapy. This philosophy is usually applied for patients facing many years of dialysis, where the placement on PD may prolong the RRF and limit lifetime demands on vascular access with consideration of modality switch if the patient loses RRF and encounters problems such as hypervolemia. Using this approach, patients starting on PD and changing to HD have had improved survival compared with those starting, and remaining, on HD [16].  [17] which states that Diabetes mellitus is the most common cause of chronic kidney disease in the world.
In the comparison between both groups regarding interdialytic weight gain there was highly statistically significant difference between groups which goes in agreement with Kimmel et al. [18], López-Gómez et al. [19] and Termorshuizen et al. [20] whose results states that average interdialytic weight gain in the group of patients with preserved RRF was also decreased significantly with respect to the average weight gain in the group of patients without preserved RRF, which Open Journal of Nephrology  [22] who states that Loss of RRF predisposes patients to poor Extra cellular volume and BP control.

Conclusion
From this study, we can conclude that preserved RRF has a significant relation with decreasing the incidence of developing hypertension in patients with ESRD on regular HD, but the relation between residual renal function and control of hypertension is not statistically significant. And more comprehensive study is needed.